Status:
UNKNOWN
Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Neovascular Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.
Eligibility Criteria
Inclusion
- Cases of active neovascular AMD with visual acuity of 20/400- 20/40
Exclusion
- History of glaucoma or ocular hypertension
- Disciform scar
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00370370
Start Date
November 1 2005
Last Update
June 26 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamid Ahmadieh, MD
Tehran, Tehran Province, Iran, 16666